(Q34266266)

1 August 2017

1 reference

title

Targeting cellular energy production in neurological disorders (English)

1 reference

1 August 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

16 March 2024

author name string

Steven K. Baker

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14519086

16 March 2024

Mark A. Tarnopolsky

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14519086

16 March 2024

language of work or name

English

0 references

publication date

1 October 2003

1 reference

full work available at URL

1 August 2017

http://www.tandfonline.com/doi/pdf/10.1517/13543784.12.10.1655

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Expert Opinion on Investigational Drugs

16 March 2024

published in

1 reference

1 August 2017

volume

12

1 reference

1 August 2017

issue

10

1 reference

1 August 2017

page(s)

1655-1679

1 reference

A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Mitochondrial disorders: clinical and genetic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Mitochondria and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Visualization of NMDA receptor-induced mitochondrial calcium accumulation in striatal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

The contribution of mitochondrial respiratory complexes to the production of reactive oxygen species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

The site of production of superoxide radical in mitochondrial Complex I is not a bound ubisemiquinone but presumably iron-sulfur cluster N2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Creatine monohydrate does not increase strength in patients with hereditary neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

The cloning and expression of a human creatine transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Creatine uptake and creatine transporter expression among rat skeletal muscle fiber types

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

The regulation of total creatine content in a myoblast cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Extracellular creatine regulates creatine transport in rat and human muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Acute and moderate-term creatine monohydrate supplementation does not affect creatine transporter mRNA or protein content in either young or elderly humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Cyclosporin A inhibits creatine uptake by altering surface expression of the creatine transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Muscle disorders associated with cyclosporine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Resynthesis of creatine phosphate in human muscle after exercise in relation to intramuscular pH and availability of oxygen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Creatine supplementation enhances anaerobic ATP synthesis during a single 10 sec maximal handgrip exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

'Hot spots' of creatine kinase localization in brain: cerebellum, hippocampus and choroid plexus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Brain creatine kinase and creatine transporter proteins in normal and creatine-treated rabbit pups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

L-2-hydroxyglutaric acid inhibits mitochondrial creatine kinase activity from cerebellum of developing rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Mitochondrial creatine kinase: a major constituent of pathological inclusions seen in mitochondrial myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Mitochondrial creatine kinase and mitochondrial outer membrane porin show a direct interaction that is modulated by calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Mitochondrial superoxide anion production and release into intermembrane space.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Rapid and irreversible inhibition of creatine kinase by peroxynitrite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Mitochondrial creatine kinase is a prime target of peroxynitrite-induced modification and inactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

The role of creatine kinase in inhibition of mitochondrial permeability transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

The role of phosphorylcreatine and creatine in the regulation of mitochondrial respiration in human skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Inhibition of the mitochondrial permeability transition by creatine kinase substrates. Requirement for microcompartmentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Direct antioxidant properties of creatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Specificity of creatine in the control of muscle protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Effects of oral creatine and resistance training on myogenic regulatory factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Dietary creatine monohydrate supplementation increases satellite cell mitotic activity during compensatory hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

The Effects of Ergogenic Compounds on Myogenic Satellite Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

The creatine kinase system is essential for optimal refill of the sarcoplasmic reticulum Ca2+ store in skeletal muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Cell volume control and signal transduction in apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Creatine deficiency syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Arginine:glycine amidinotransferase deficiency: the third inborn error of creatine metabolism in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Creatine deficiency in the brain: a new, treatable inborn error of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Lack of creatine in muscle and brain in an adult with GAMT deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

X-linked creatine-transporter gene (SLC6A8) defect: a new creatine-deficiency syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

The clinical syndrome of creatine transporter deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Brain creatine phosphate and creatine kinase in mice fed an analogue of creatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

The expression of lactate transporters (MCT1 and MCT4) in heart and muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Fasting modulates creatine entry into skeletal muscle in the mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Reduced brain creatine in gyrate atrophy of the choroid and retina with hyperornithinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Creatine and cyclocreatine attenuate MPTP neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Magnetic resonance imaging and 1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

No effect of creatine on respiratory distress in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Mitochondrial defect in Huntington's disease caudate nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Energy metabolism defects in Huntington's disease and effects of coenzyme Q10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Clinical correlation of striatal 1H MRS changes in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Metabolic changes in quinolinic acid-lesioned rat striatum detected non-invasively by in vivo (1)H NMR spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Beneficial effects of creatine supplementation in dystrophic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Creatine monohydrate in DM2/PROMM: a double-blind placebo-controlled clinical study. Proximal myotonic myopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Creatine monohydrate increases strength in patients with neuromuscular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Skeletal muscle metabolism in myotonic dystrophy A 31P magnetic resonance spectroscopy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Effect of creatine supplementation on creatine and glycogen content in rat skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Muscle glycogen supercompensation is enhanced by prior creatine supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Exercise to exhaustion in the second-wind phase of exercise in a case of McArdle's disease with and without creatine supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Role of creatine and phosphocreatine in neuronal protection from anoxic and ischemic damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Anoxic ATP depletion in neonatal mice brainstem is prevented by creatine supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Neuroprotection of creatine supplementation in neonatal rats with transient cerebral hypoxia-ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Protective effects of oral creatine supplementation on spinal cord injury in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Influence of oral creatine supplementation of muscle torque during repeated bouts of maximal voluntary exercise in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Effect of short-term creatine supplementation on renal responses in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Long-term oral creatine supplementation does not impair renal function in healthy athletes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Cytotoxicity assessment of Ma-huang (Ephedra) under different conditions of preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Clinical implications of the correlation between coenzyme Q10 and vitamin B6 status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Lovastatin, isoprenes, and myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Discharge of newly-synthesized dolichol and ubiquinone with lipoproteins to rat liver perfusate and to the bile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Uptake of exogenous coenzyme Q and transport to mitochondria is required for bc1 complex stability in yeast coq mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Biochemical, physiological and medical aspects of ubiquinone function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Effects of coenzyme Q10 and alpha-tocopherol administration on their tissue levels in the mouse: elevation of mitochondrial alpha-tocopherol by coenzyme Q10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Biochemical functions of coenzyme Q10

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Protection of cultured oligodendrocytes against tumor necrosis factor-alpha by the antioxidants coenzyme Q(10) and N-acetyl cysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Reactive oxygen species mediate the down-regulation of mitochondrial transcripts and proteins by tumour necrosis factor-alpha in L929 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Plasma membrane redox system in the control of stress-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Regulation of the mitochondrial permeability transition pore by ubiquinone analogs. A progress report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Ceramide-dependent caspase 3 activation is prevented by coenzyme Q from plasma membrane in serum-deprived cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Neuroprotective Effects of Coenzyme Q10 at Rostral Ventrolateral Medulla Against Fatality During Experimental Endotoxemia in the Rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Dual involvement of coenzyme Q10 in redox signaling and inhibition of death signaling in the rat heart mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Mitochondrial ROS metabolism: modulation by uncoupling proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Uncoupling proteins 2 and 3 are highly active H(+) transporters and highly nucleotide sensitive when activated by coenzyme Q (ubiquinone)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Superoxide activates mitochondrial uncoupling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Coenzyme Q10 as a possible treatment for neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Effect of coenzyme Q10 supplementation on mitochondrial function after myocardial ischemia reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Effect of coenzyme Q(10) on biochemical and morphological changes in experimental ischemia in the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Aminooxyacetic acid striatal lesions attenuated by 1,3-butanediol and coenzyme Q10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Molecular mechanisms of glutamate neurotoxicity in mixed cultures of NT2-derived neurons and astrocytes: protective effects of coenzyme Q10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

MPP+ produces progressive neuronal degeneration which is mediated by oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Assessment of coenzyme Q10 tolerability in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

A controlled trial of idebenone in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Distribution of coenzyme Q homologues in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Mitochondrial complex I deficiency in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Coenzyme Q-responsive Leigh's encephalopathy in two sisters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

d-Cycloserine enhances implicit memory in Alzheimer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Cerebellar ataxia and coenzyme Q10 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Coenzyme Q cytoprotective mechanisms for mitochondrial complex I cytopathies involves NAD(P)H: quinone oxidoreductase 1(NQO1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Choreic movements and MRI abnormalities in the subthalamic nuclei reversible after administration of coenzyme Q10 and multiple vitamins in a patient with bilateral optic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Idebenone in patients with Friedreich ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Neuroprotective effects of alpha-lipoic acid and its enantiomers demonstrated in rodent models of focal cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Beta-hydroxy-beta-methylbutyrate ingestion, Part I: effects on strength and fat free mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Nutritional supplementation of the leucine metabolite beta-hydroxy-beta-methylbutyrate (hmb) during resistance training.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Nicotinamide reduces infarction up to two hours after the onset of permanent focal cerebral ischemia in Wistar rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Decreases in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Nicotinamide attenuates focal ischemic brain injury in rats: with special reference to changes in nicotinamide and NAD+ levels in ischemic core and penumbra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

MELAS syndrome with mitochondrial tRNA(Leu)(UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Mitochondrial myopathy with tRNA(Leu(UUR)) mutation and complex I deficiency responsive to riboflavin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Riboflavin responsive multiple acyl-CoA dehydrogenase deficiency: Functional evaluation of recovery after high dose vitamin supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Oral administration of creatine monohydrate retards progression of motor neuron disease in the wobbler mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Ca2+ -reversible inhibition of the mitochondrial megachannel by ubiquinone analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Protection against peroxynitrite-dependent tyrosine nitration and α 1 -antiproteinase inactivation by oxidized and reduced lipoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Creatine supplementation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Influence of Folic Acid and Vitamin B12 on Formation of Creatine in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Protective Effect of the Energy Precursor Creatine Against Toxicity of Glutamate and β-Amyloid in Rat Hippocampal Neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Coenzyme Q is an obligatory cofactor for uncoupling protein function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.10.1655

Altered Ca2+ responses in muscles with combined mitochondrial and cytosolic creatine kinase deficiencies

21 January 2018

4

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Hydroperoxide metabolism in mammalian organs

16 March 2024

9

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Creatine and creatinine metabolism

16 March 2024

12

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Creatine: Biosynthesis, Regulation, and Function

16 March 2024

14

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Creatine uptake in isolated soleus muscle: kinetics and dependence on sodium, but not on insulin

16 March 2024

20

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Contribution of phosphocreatine and aerobic metabolism to energy supply during repeated sprint exercise

16 March 2024

27

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Recovery of power output and muscle metabolites following 30 s of maximal sprint cycling in man

16 March 2024

28

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondrial disease

16 March 2024

30

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Brain metabolism in hypothyroidism studied with 31P magnetic-resonance spectroscopy

16 March 2024

33

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Reduced maximum shortening velocity in the absence of phosphocreatine observed in intact fibres of Xenopus skeletal muscle

16 March 2024

34

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Reversible S-nitrosation of creatine kinase by nitric oxide in adult rat ventricular myocytes

16 March 2024

47

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Nitric oxide inhibits cardiac energy production via inhibition of mitochondrial creatine kinase

16 March 2024

48

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.

16 March 2024

53

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

The effect of creatine monohydrate ingestion on anaerobic power indices, muscular strength and body composition

16 March 2024

59

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Acute creatine loading increases fat-free mass, but does not affect blood pressure, plasma creatinine, or CK activity in men and women

16 March 2024

60

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Effects of acute creatine monohydrate supplementation on leucine kinetics and mixed-muscle protein synthesis

16 March 2024

61

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Shortening of muscle relaxation time after creatine loading.

16 March 2024

65

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Brain creatine depletion: Guanidinoacetate methyltransferase deficiency (improving with creatine supplementation)

16 March 2024

72

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Brain metabolism in hypothyroidism studied with 31P magnetic-resonance spectroscopy

16 March 2024

79

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina

16 March 2024

84

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Phosphocreatine-dependent Glutamate Uptake by Synaptic Vesicles

16 March 2024

91

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy

16 March 2024

104

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease.

16 March 2024

106

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats

16 March 2024

110

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.

16 March 2024

111

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Neuroprotective effects of creatine administration against NMDA and malonate toxicity

16 March 2024

114

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies

16 March 2024

118

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Supplementation with creatine monohydrate in children with mitochondrial encephalomyopathies

16 March 2024

119

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease

16 March 2024

122

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study

16 March 2024

123

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Oral creatine supplementation in Duchenne muscular dystrophy: a clinical and 31P magnetic resonance spectroscopy study

16 March 2024

124

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial

16 March 2024

129

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Cellular energetics of dystrophic muscle

16 March 2024

132

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Dietary supplement creatine protects against traumatic brain injury

16 March 2024

142

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Muscle creatine loading in men.

16 March 2024

144

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Renal dysfunction accompanying oral creatine supplements

16 March 2024

150

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies

16 March 2024

156

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome

16 March 2024

161

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle

16 March 2024

165

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Coenzyme Q10, Alpha-Tocopherol and Free Cholesterol in HDL and LDL Fractions

16 March 2024

169

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Differences between carnitine derivatives and coenzyme Q10 in preventing in vitro doxorubicin-related cardiac damages

16 March 2024

174

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Coenzyme Q10 treatment in serious heart failure

16 March 2024

175

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study

16 March 2024

176

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

An analysis of the role of coenzyme Q in free radical generation and as an antioxidant

16 March 2024

177

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria

16 March 2024

179

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Lipid peroxidation and changes in the ubiquinone content and the respiratory chain enzymes of submitochondrial particles

16 March 2024

180

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Effect of coenzyme Q(10) and alpha-tocopherol content of mitochondria on the production of superoxide anion radicals

16 March 2024

183

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

In vivo supplementation with coenzyme Q10 enhances the recovery of human lymphocytes from oxidative DNA damage

16 March 2024

188

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Coenzyme Q protects cells against serum withdrawal-induced apoptosis by inhibition of ceramide release and caspase-3 activation

16 March 2024

196

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency

16 March 2024

198

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Cellular redox activity of coenzyme Q10: effect of CoQ10 supplementation on human skeletal muscle

16 March 2024

201

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate

16 March 2024

213

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases

16 March 2024

214

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.

16 March 2024

217

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Involvement of free radicals in MPP+ neurotoxicity against rat dopaminergic neurons in culture

16 March 2024

219

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles

16 March 2024

221

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity

16 March 2024

222

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease

16 March 2024

226

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease

16 March 2024

237

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Muscle coenzyme Q10 in mitochondrial encephalomyopathies

16 March 2024

245

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Long-term coenzyme Q10 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency: a 31P NMR study

16 March 2024

248

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies

16 March 2024

250

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Correction of pancreatic beta-cell dysfunction with coenzyme Q(10) in a patient with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome and diabetes mellitus

16 March 2024

252

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Rapid visual recovery after coenzyme q10 treatment of leber hereditary optic neuropathy

16 March 2024

253

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathy

16 March 2024

266

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy

16 March 2024

269

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Beta-hydroxy-beta-methylbutyrate ingestion, part II: effects on hematology, hepatic and renal function

16 March 2024

274

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Body composition in 70-year-old adults responds to dietary beta-hydroxy-beta-methylbutyrate similarly to that of young adults

16 March 2024

277

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Effects of beta-hydroxy-beta-methylbutyrate on muscle damage after a prolonged run.

16 March 2024

279

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

beta-hydroxy-beta-methylbutyrate (HMB) supplementation in humans is safe and may decrease cardiovascular risk factors.

16 March 2024

280

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Increase of blood NAD+ and attenuation of lactacidemia during nicotinamide treatment of a patient with the MELAS syndrome

16 March 2024

286

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Treatment of complex I deficiency with riboflavin

16 March 2024

288

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Late-onset riboflavin-responsive myopathy with combined multiple acyl coenzyme A dehydrogenase and respiratory chain deficiency

16 March 2024

291

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

Effect of deprenyl on the progression of disability in early Parkinson's disease

16 March 2024

294

1 reference

https://api.crossref.org/works/10.1517/13543784.12.10.1655

16 March 2024

Identifiers

1 reference

1 August 2017

1 reference